{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:11:08Z","timestamp":1793142668331,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Ono Pharmaceutical Co., Ltd."},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cancer of unknown primary (CUP) is associated with poor prognosis. In December 2021, nivolumab was approved in Japan for the treatment of CUP based on a small phase II trial. This post-marketing surveillance (PMS) evaluated the real-world safety and effectiveness of nivolumab in Japanese patients with CUP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This prospective, observational, PMS enrolled patients with CUP who initiated nivolumab between April 2022 and June 2023 at 66 institutions. Patients were observed for 6\u00a0months. Safety outcomes were treatment-related adverse events (TRAEs), and effectiveness outcomes included overall response rate (ORR) and overall survival (OS). Analyses were descriptive.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 151 patients in the safety set, the median age was 70\u00a0years and 79.5% had an Eastern Cooperative Oncology Group performance status (PS) 0\u20131. Any grade and Grade\u2009\u2265\u20093 TRAEs occurred in 25.2% and 11.9% of patients, respectively. Frequently reported TRAEs included interstitial lung disease (3.3%), hepatic function abnormal (2.6%), and hypothyroidism (2.6%). There was one TRAE (neutropenia) resulting in death. In the effectiveness set (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009144), the ORR was 21.5%. ORR was higher in patients without prior systemic therapy (25.4% vs. 18.2%) and in those with lymph node-only involvement (36.6% vs. 15.5%). The 6-month OS rate was 71.0%, and median OS was not reached. The 6-month OS rates were greater in patients with PS 0\u20131 and lymph node-only involvement.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Nivolumab was tolerated in patients with CUP in routine practice in Japan, with no new safety concerns, and indicated antitumor activity consistent with clinical trial results.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>Japan Registry of Clinical Trials (jRCT2041240121).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10147-026-03147-3","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T11:43:23Z","timestamp":1787744603000},"page":"2363-2373","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-world safety and effectiveness of nivolumab in patients with cancer of unknown primary: results from a nationwide post-marketing surveillance in Japan"],"prefix":"10.1007","volume":"31","author":[{"given":"Akira","family":"Kawasaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akito","family":"Kakuuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayumi","family":"Akamatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misato","family":"Nakanishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chikara","family":"Honda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"key":"3147_CR1","unstructured":"Stevenson MM, Bowles DW, Abughanimeh O et al (2025) NCCN clinical practice guidelines in oncology: occult primary (Cancer of Unknown Primary [CUP]) Version 2.2025. National Comprehensive Cancer Network"},{"key":"3147_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2021.102204","volume":"97","author":"T Olivier","year":"2021","unstructured":"Olivier T, Fernandez E, Labidi-Galy I et al (2021) Redefining cancer of unknown primary: Is precision medicine really shifting the paradigm? Cancer Treat Rev 97:102204. https:\/\/doi.org\/10.1016\/j.ctrv.2021.102204","journal-title":"Cancer Treat Rev"},{"key":"3147_CR3","doi-asserted-by":"publisher","first-page":"3919","DOI":"10.7150\/jca.42880","volume":"11","author":"AT Alshareeda","year":"2020","unstructured":"Alshareeda AT, Al-Sowayan BS, Alkharji RR et al (2020) Cancer of unknown primary site: Real entity or misdiagnosed disease? J Cancer 11:3919\u20133931. https:\/\/doi.org\/10.7150\/jca.42880","journal-title":"J Cancer"},{"key":"3147_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105312","volume":"10","author":"HR Robinson","year":"2025","unstructured":"Robinson HR, Lakritz S, Pavlick DC et al (2025) Squamous cell carcinoma of unknown primary (SCCUP): a genomic landscape study. ESMO Open 10:105312. https:\/\/doi.org\/10.1016\/j.esmoop.2025.105312","journal-title":"ESMO Open"},{"key":"3147_CR5","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1007\/s10147-022-02155-3","volume":"27","author":"H Uemura","year":"2022","unstructured":"Uemura H, Tomita Y, Nonomura N et al (2022) Real-world safety and effectiveness of nivolumab for advanced renal cell carcinoma in Japan: a post-marketing surveillance. Int J Clin Oncol 27:1061\u20131067. https:\/\/doi.org\/10.1007\/s10147-022-02155-3","journal-title":"Int J Clin Oncol"},{"key":"3147_CR6","unstructured":"Ono Pharmaceutical Co., Ltd. (2025) Opdivo\u00ae (nivolumab) interview form [in Japanese]. Ono Pharmaceutical Co., Ltd. https:\/\/pins.japic.or.jp\/pdf\/medical_interview\/IF00008683.pdf. Accessed September 11, 2025"},{"key":"3147_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005809","author":"A Posner","year":"2023","unstructured":"Posner A, Sivakumaran T, Pattison A et al (2023) Immune and genomic biomarkers of immunotherapy response in cancer of unknown primary. J Immunother Cancer 11:e005809. https:\/\/doi.org\/10.1136\/jitc-2022-005809","journal-title":"J Immunother Cancer"},{"key":"3147_CR8","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1186\/s40425-019-0720-z","volume":"7","author":"K Haratani","year":"2019","unstructured":"Haratani K, Hayashi H, Takahama T et al (2019) Clinical and immune profiling for cancer of unknown primary site. J Immunother Cancer 7:251. https:\/\/doi.org\/10.1186\/s40425-019-0720-z","journal-title":"J Immunother Cancer"},{"key":"3147_CR9","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.annonc.2021.11.009","volume":"33","author":"J Tanizaki","year":"2022","unstructured":"Tanizaki J, Yonemori K, Akiyoshi K et al (2022) Open-label phase II study of the efficacy of nivolumab for cancer of unknown primary. Ann Oncol 33:216\u2013226. https:\/\/doi.org\/10.1016\/j.annonc.2021.11.009","journal-title":"Ann Oncol"},{"key":"3147_CR10","doi-asserted-by":"publisher","first-page":"65","DOI":"10.4103\/sajc.sajc_167_18","volume":"8","author":"VG Gupta","year":"2019","unstructured":"Gupta VG, Rangaraju RR, Abbas W et al (2019) Immune checkpoint inhibitors: real-world experience from India in advanced solid cancers that have progressed on chemotherapy. South Asian J Cancer 8:65\u201368. https:\/\/doi.org\/10.4103\/sajc.sajc_167_18","journal-title":"South Asian J Cancer"},{"key":"3147_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-02543-1","volume":"11","author":"S Kang","year":"2021","unstructured":"Kang S, Jeong JH, Yoon S et al (2021) Real-world data analysis of patients with cancer of unknown primary. Sci Rep 11:23074. https:\/\/doi.org\/10.1038\/s41598-021-02543-1","journal-title":"Sci Rep"},{"key":"3147_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.7052","volume":"13","author":"EL Boys","year":"2024","unstructured":"Boys EL, Gao B, Grimison P et al (2024) Retrospective analysis of clinical characteristics and outcomes of patients with carcinoma of unknown primary from three tertiary centers in Australia. Cancer Med 13:e7052. https:\/\/doi.org\/10.1002\/cam4.7052","journal-title":"Cancer Med"},{"key":"3147_CR13","doi-asserted-by":"publisher","first-page":"185","DOI":"10.3892\/ol.2025.14929","volume":"29","author":"M Ma","year":"2025","unstructured":"Ma M, Guo B, Duan Q et al (2025) Clinical characteristics and survival analysis of cancer of unknown primary. Oncol Lett 29:185. https:\/\/doi.org\/10.3892\/ol.2025.14929","journal-title":"Oncol Lett"},{"key":"3147_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-025-14778-6","volume":"25","author":"H Wang","year":"2025","unstructured":"Wang H, Song S, Nie Y et al (2025) Clinical efficacy of immune checkpoint inhibitors for cancer of unknown primary: a multi-center retrospective study. BMC Cancer 25:1323. https:\/\/doi.org\/10.1186\/s12885-025-14778-6","journal-title":"BMC Cancer"},{"key":"3147_CR15","unstructured":"Pharmaceuticals and Medical Devices Agency (PMDA) (2021) Clinical summary (application data) for nivolumab (ONO-4538). PMDA. https:\/\/www.pmda.go.jp\/drugs\/2021\/P20211213002\/index.html. Accessed November 21, 2025"},{"key":"3147_CR16","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1111\/1346-8138.16432","volume":"49","author":"H Uhara","year":"2022","unstructured":"Uhara H, Tsuchida T, Kiyohara Y et al (2022) Safety and effectiveness of nivolumab in Japanese patients with malignant melanoma: final analysis of a post-marketing surveillance. J Dermatol 49:862\u2013871. https:\/\/doi.org\/10.1111\/1346-8138.16432","journal-title":"J Dermatol"},{"key":"3147_CR17","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1007\/s10147-021-01949-1","volume":"26","author":"M Tahara","year":"2021","unstructured":"Tahara M, Kiyota N, Nibu KI et al (2021) Real-world safety and effectiveness of nivolumab for recurrent or metastatic head and neck cancer in Japan: a post-marketing surveillance. Int J Clin Oncol 26:1619\u20131627. https:\/\/doi.org\/10.1007\/s10147-021-01949-1","journal-title":"Int J Clin Oncol"},{"key":"3147_CR18","doi-asserted-by":"publisher","first-page":"4692","DOI":"10.1111\/cas.15117","volume":"112","author":"N Yamamoto","year":"2021","unstructured":"Yamamoto N, Nakanishi Y, Gemma A et al (2021) Real-world safety of nivolumab in patients with non-small-cell lung cancer in Japan: postmarketing surveillance. Cancer Sci 112:4692\u20134701. https:\/\/doi.org\/10.1111\/cas.15117","journal-title":"Cancer Sci"},{"key":"3147_CR19","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1007\/s10147-024-02515-1","volume":"29","author":"K Hiraizumi","year":"2024","unstructured":"Hiraizumi K, Honda C, Watanabe A et al (2024) Safety of nivolumab monotherapy in five cancer types: pooled analysis of post-marketing surveillance in Japan. Int J Clin Oncol 29:932\u2013943. https:\/\/doi.org\/10.1007\/s10147-024-02515-1","journal-title":"Int J Clin Oncol"},{"key":"3147_CR20","doi-asserted-by":"publisher","first-page":"2352","DOI":"10.1002\/cam4.2868","volume":"9","author":"S Byeon","year":"2020","unstructured":"Byeon S, Cho JH, Jung HA et al (2020) PD-1 inhibitors for non-small cell lung cancer patients with special issues: real-world evidence. Cancer Med 9:2352\u20132362. https:\/\/doi.org\/10.1002\/cam4.2868","journal-title":"Cancer Med"},{"key":"3147_CR21","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.ejca.2021.08.030","volume":"157","author":"K Saleh","year":"2021","unstructured":"Saleh K, Auperin A, Martin N et al (2021) Efficacy and safety of immune checkpoint inhibitors in elderly patients (\u226570 years) with squamous cell carcinoma of the head and neck. Eur J Cancer 157:190\u2013197. https:\/\/doi.org\/10.1016\/j.ejca.2021.08.030","journal-title":"Eur J Cancer"},{"key":"3147_CR22","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.21037\/jtd-22-93","volume":"14","author":"S Kim","year":"2022","unstructured":"Kim S, Lim JU (2022) Immune checkpoint inhibitor-related interstitial lung disease in patients with advanced non-small cell lung cancer: systematic review of characteristics, incidence, risk factors, and management. J Thorac Dis 14:1684\u20131695. https:\/\/doi.org\/10.21037\/jtd-22-93","journal-title":"J Thorac Dis"},{"key":"3147_CR23","doi-asserted-by":"publisher","first-page":"e194","DOI":"10.1093\/oncolo\/oyab036","volume":"27","author":"ML Gillison","year":"2022","unstructured":"Gillison ML, Blumenschein G, Fayette J et al (2022) Long-term outcomes with nivolumab as first-line treatment in recurrent or metastatic head and neck cancer: subgroup analysis of CheckMate 141. Oncologist 27:e194\u2013e198. https:\/\/doi.org\/10.1093\/oncolo\/oyab036","journal-title":"Oncologist"},{"key":"3147_CR24","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.eururo.2019.10.004","volume":"77","author":"A G\u00f3mez de Lia\u00f1o Lista","year":"2020","unstructured":"G\u00f3mez de Lia\u00f1o Lista A, van Dijk N, de Velasco Oria de Rueda G et al (2020) Clinical outcome after progressing to frontline and second-line anti-PD-1\/PD-L1 in advanced urothelial cancer. Eur Urol 77:269\u2013276. https:\/\/doi.org\/10.1016\/j.eururo.2019.10.004","journal-title":"Eur Urol"},{"key":"3147_CR25","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1111\/1346-8138.16518","volume":"49","author":"N Yamazaki","year":"2022","unstructured":"Yamazaki N, Shimizu A, Ozaki M et al (2022) Real-world safety and effectiveness of pembrolizumab in Japanese patients with radically unresectable melanoma: an all-case postmarketing surveillance in Japan. J Dermatol 49:1096\u20131105. https:\/\/doi.org\/10.1111\/1346-8138.16518","journal-title":"J Dermatol"},{"key":"3147_CR26","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1056\/NEJMcp2402691","volume":"392","author":"K Raghav","year":"2025","unstructured":"Raghav K (2025) Cancer of unknown primary site. N Engl J Med 392:2035\u20132047. https:\/\/doi.org\/10.1056\/NEJMcp2402691","journal-title":"N Engl J Med"},{"key":"3147_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46769-9","volume":"15","author":"D Maggiorani","year":"2024","unstructured":"Maggiorani D, Le O, Lisi V et al (2024) Senescence drives immunotherapy resistance by inducing an immunosuppressive tumor microenvironment. Nat Commun 15:2435. https:\/\/doi.org\/10.1038\/s41467-024-46769-9","journal-title":"Nat Commun"},{"key":"3147_CR28","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1001\/jamaoto.2022.0640","volume":"148","author":"HH Alkhatib","year":"2022","unstructured":"Alkhatib HH, Maroun CA, Amin N et al (2022) Tumor histological grade and immunotherapy response in patients with recurrent or metastatic head and neck squamous cell carcinoma. JAMA Otolaryngol Head Neck Surg 148:540\u2013546. https:\/\/doi.org\/10.1001\/jamaoto.2022.0640","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"3147_CR29","doi-asserted-by":"publisher","first-page":"794","DOI":"10.3390\/cancers14030794","volume":"14","author":"EJ Park","year":"2022","unstructured":"Park EJ, Park HJ, Kim KW et al (2022) Efficacy of immune checkpoint inhibitors against advanced or metastatic neuroendocrine neoplasms: a systematic review and meta-analysis. Cancers (Basel) 14:794. https:\/\/doi.org\/10.3390\/cancers14030794","journal-title":"Cancers (Basel)"},{"key":"3147_CR30","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010958","volume":"13","author":"MJ Moussa","year":"2025","unstructured":"Moussa MJ, Khandelwal J, Wilson NR et al (2025) Efficacy and safety of nivolumab plus ipilimumab in patients with metastatic variant histology (non-clear cell) renal cell carcinoma. J Immunother Cancer 13:e010958. https:\/\/doi.org\/10.1136\/jitc-2024-010958","journal-title":"J Immunother Cancer"},{"key":"3147_CR31","doi-asserted-by":"publisher","first-page":"7413","DOI":"10.1158\/1078-0432.Ccr-19-0558","volume":"25","author":"L Liu","year":"2019","unstructured":"Liu L, Bai X, Wang J et al (2019) Combination of TMB and CNA stratifies prognostic and predictive responses to immunotherapy across metastatic cancer. Clin Cancer Res 25:7413\u20137423. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-19-0558","journal-title":"Clin Cancer Res"},{"key":"3147_CR32","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1002\/gcc.23047","volume":"61","author":"T Bochtler","year":"2022","unstructured":"Bochtler T, Wohlfromm T, Hielscher T et al (2022) Prognostic impact of copy number alterations and tumor mutational burden in carcinoma of unknown primary. Genes Chromosomes Cancer 61:551\u2013560. https:\/\/doi.org\/10.1002\/gcc.23047","journal-title":"Genes Chromosomes Cancer"},{"key":"3147_CR33","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.lungcan.2020.04.027","volume":"145","author":"FG Dall'Olio","year":"2020","unstructured":"Dall\u2019Olio FG, Maggio I, Massucci M et al (2020) ECOG performance status \u22652 as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitors\u2014A systematic review and meta-analysis of real world data. Lung Cancer 145:95\u2013104. https:\/\/doi.org\/10.1016\/j.lungcan.2020.04.027","journal-title":"Lung Cancer"},{"key":"3147_CR34","doi-asserted-by":"publisher","first-page":"4104","DOI":"10.1002\/cam4.4722","volume":"11","author":"C Chalker","year":"2022","unstructured":"Chalker C, Voutsinas JM, Wu QV et al (2022) Performance status (PS) as a predictor of poor response to immune checkpoint inhibitors (ICI) in recurrent\/metastatic head and neck cancer (RMHNSCC) patients. Cancer Med 11:4104\u20134111. https:\/\/doi.org\/10.1002\/cam4.4722","journal-title":"Cancer Med"},{"key":"3147_CR35","doi-asserted-by":"publisher","first-page":"e175","DOI":"10.1200\/op.20.01055","volume":"18","author":"M Krishnan","year":"2022","unstructured":"Krishnan M, Kasinath P, High R et al (2022) Impact of performance status on response and survival among patients receiving checkpoint inhibitors for advanced solid tumors. JCO Oncol Pract 18:e175\u2013e182. https:\/\/doi.org\/10.1200\/op.20.01055","journal-title":"JCO Oncol Pract"},{"key":"3147_CR36","doi-asserted-by":"publisher","first-page":"37","DOI":"10.36401\/jipo-22-3","volume":"5","author":"L Wells","year":"2022","unstructured":"Wells L, Cerniglia M, Hall S et al (2022) Treatment of metastatic disease with immune checkpoint inhibitors nivolumab and pembrolizumab: effect of performance status on clinical outcomes. J Immunother Precis Oncol 5:37\u201342. https:\/\/doi.org\/10.36401\/jipo-22-3","journal-title":"J Immunother Precis Oncol"},{"key":"3147_CR37","doi-asserted-by":"publisher","first-page":"6761","DOI":"10.1038\/s41467-023-42400-5","volume":"14","author":"M Pouyiourou","year":"2023","unstructured":"Pouyiourou M, Kraft BN, Wohlfromm T et al (2023) Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial. Nat Commun 14:6761. https:\/\/doi.org\/10.1038\/s41467-023-42400-5","journal-title":"Nat Commun"},{"key":"3147_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100577","volume":"7","author":"CM Kim","year":"2022","unstructured":"Kim CM, Lee JB, Shin SJ et al (2022) The efficacy of immune checkpoint inhibitors in elderly patients: a meta-analysis and meta-regression. ESMO Open 7:100577. https:\/\/doi.org\/10.1016\/j.esmoop.2022.100577","journal-title":"ESMO Open"},{"key":"3147_CR39","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.annonc.2022.11.013","volume":"34","author":"A Kr\u00e4mer","year":"2023","unstructured":"Kr\u00e4mer A, Bochtler T, Pauli C et al (2023) Cancer of unknown primary: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 34:228\u2013246. https:\/\/doi.org\/10.1016\/j.annonc.2022.11.013","journal-title":"Ann Oncol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03147-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-026-03147-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03147-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:50:16Z","timestamp":1790355016000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-026-03147-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,26]]},"references-count":39,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["3147"],"URL":"https:\/\/doi.org\/10.1007\/s10147-026-03147-3","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,26]]},"assertion":[{"value":"17 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors are employees of Ono Pharmaceutical Co., Ltd. The authors declare that they have no other conflicts of interest related to this work.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This PMS conformed to Japanese Good Post-Marketing Study Practice regulations. Each participating hospital agreed to contracts for this PMS with the study sponsor. Since all treatments were at the physician\u2019s discretion in actual clinical practice and no interventions were made for the purpose of this study, written informed consent was not required under Good Post-Marketing Study Practice.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}